Overview
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.
The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
Description
8 hospitals of the Catholic University of Korea with high-volume percutaneous coronary intervention of following hospitals are participating in the current study.
Seoul St. Mary's Hospital, Seoul, South Korea
Yeoido St. Mary's Hospital, Seoul, South Korea
Uijongbu St. Mary's Hospital, Gyeonggi-do, South Korea
Eunpyeong St. Mary's Hospital, Seoul, South Korea
Bucheon St. Mary's Hospital, Gyeonggi-do, South Korea
Incheon St. Mary's Hospital, Incheon, South Korea
St. Vincent Hospital, Gyeonggi-do, South Korea
Daejeon St. Mary's Hospital, Daejeon, South Korea
After recruitment of all patients, the control group will be selected from a previous prospective cohort (COREA-AMI, NCT02385682) using identical inclusion / exclusion criteria except for use of SGLT2 inhibitors. The control cohort of 3,000 patients will be selected using 1:3 propensity matching.
Eligibility
Inclusion Criteria:
- Acute myocardial infarction who were treated with percutaneous coronary intervention
- Type 2 diabetes mellitus
- Started SGLT2 inhibitors <1 month before/after PCI
Exclusion Criteria:
- Type 1 diabetes mellitus
- Insulin / GLP-1 analogue users
- Previous users of SGLT2 inhibitors
- Pregnancy